Life Science News

RSS

Cytori Therapeutics Q2 2009 financial results

Total revenues were $8.5 million and $10.5 million for the three and six months ended June 30, 2009, respectively, compared to $1.4 million and $2.4 million for the same periods in 2008. As part of Cytori’s Olympus partnership, the Company recognized $7.3 million in development revenue in the second quarter of 2009, due mostly to the completion of enrollment in the cardiovascular disease clinical safety and feasibility studies.

From Evident Corporation - Life Sciences 10 Aug 2009

The navel shown to be a safe and effective single access route for extracting kidneys

Successful surgery that leaves no scars has become the main objective of the most daring and innovative surgeons.

From Evident Corporation - Life Sciences 12 Mar 2009

New tool for 'right first time' drug manufacture

A technology which provides high quality images of the crystallisation process marks the next step towards a 'right first time' approach to drug manufacture, according to engineers at the University of Leeds.

From Malvern Panalytical 23 Sep 2008

Appendix removed through a patient's vagina

On March 26, 2008, surgeons at UC San Diego Medical Center removed an inflamed appendix through a patient's vagina, a first in the United States.

From Evident Corporation - Life Sciences 31 Mar 2008

Thermo Fisher Scientific creates breakthrough gene-silencing tool

Thermo Fisher Scientific Inc. has developed a breakthrough gene-silencing tool that greatly simplifies RNA- interference (RNAi) technology and eliminates barriers associated with previous cellular delivery methods.

From Thermo Fisher Scientific Inc. 12 Mar 2008

New advances in miRNA

miRNA research is now one of the most interesting areas in the life science world, reports Genetic Engineering and Biotechnology News (GEN).

From Thermo Fisher Scientific Inc. 3 Mar 2008

Breakthrough innovation for high sensitivity TB and Malaria diagnostics

At this year's 39th World Forum for Medicine in Dusseldorf (MEDICA, November 14-17), Partec, a globally leading developer, manufacturer and provider of dedicated diagnostic solutions in the response to HIV/AIDS, Tuberculosis and Malaria is presenting a breakthrough innovation for high sensitivity TB and Malaria diagnostics in low- and middle-income countries.

15 Nov 2007

Gallbladder removed through vagina

Surgeons at the University of California, San Diego Medical Center have performed the first clinical trial surgery in the Southwest to evaluate the safety and effectiveness of performing abdominal procedures through the body's natural openings, virtually eliminating scarring.

From Evident Corporation - Life Sciences 13 Sep 2007

FDA approves new Roche direct detection of West Nile Virus in donated human blood

Roche Diagnostics announced that the US Food & Drug Administration (FDA) has approved its biologics license application for the company's test for direct detection of West Nile Virus in donated human blood and plasma.

From Roche Sequencing and Life Science 29 Aug 2007

Fast market penetration for Roche HIV viral load monitoring test

One-third of Roche Diagnostics' molecular customer base has already purchased or ordered the COBAS AmpliPrep /COBAS TaqMan HIV-1 assay, just eight weeks after the assay received approval from the Food & Drug Administration to go to market.

From Roche Sequencing and Life Science 17 Jul 2007

Spectral launches rapid West Nile test in U.S.

Spectral Diagnostics has announced the conclusion of an agreement with Fisher Healthcare, a division of Thermo Fisher Scientific Inc., for the distribution of its RapidWN West Nile Virus Test in the United States.

From Thermo Fisher Scientific Inc. 4 Jul 2007

Roche makes offer to acquire Ventana Medical Systems

Roche will make a tender offer to acquire all outstanding shares of common stock of Ventana Medical Systems for $75.00 per share in cash, or an aggregate of approximately $3 billion on a fully diluted basis.

From Roche Sequencing and Life Science 26 Jun 2007

Roche to acquire BioVeris

BioVeris Corporation has announced that the Company has reached a definitive agreement under which Roche will acquire BioVeris for $21.50 per share in cash, or a total of approximately $600 million.

From Roche Sequencing and Life Science 5 Apr 2007

FDA accepts two Roche diagnostics HPV tests for review

Roche has announced today that the United States (U.S.) Food & Drug Administration has accepted for review its applications for two human papillomavirus (HPV) tests.

From Roche Sequencing and Life Science 6 Mar 2007

Evotec sells single molecule detection technology to Olympus

Evotec AG has announced that its Tools and Technologies Division has sold the core of its Single Molecule Detection Technology and transferred or licensed the corresponding IP portfolio to Olympus Corporation, Tokyo, Japan.

From Evident Corporation - Life Sciences 24 Jul 2006